

Using machine learning for personalized prediction of revision paranasal sinus surgery

Mikko Nuutinen¹, Jari Haukka², Paula Virkkula³, Paulus Torkki², and Sanna Toppila-Salmi¹

¹Helsingin yliopisto Medicum yksikko

²Helsingin yliopisto Kansanterveystieteen osasto

³Helsingin yliopistollinen keskussairaala Paa- ja kaulakeskus

June 24, 2021

Abstract

Background: Uncontrolled chronic rhinosinusitis (CRS) needing consideration of surgery is a growing health problem yet its risk factors at individual level are not known. Our aim was to examine risk factors of revision endoscopic sinus surgery (ESS) at the individual level by using artificial intelligence. **Methods:** Demographic and visit variables were collected from electronic health records (EHR) of 790 operated CRS patients. The effect of variables on the prediction accuracy of revision ESS was examined at the individual level via machine learning models. **Results:** Revision ESS was performed to 114 (14.7%) CRS patients. The logistic regression, gradient boosting and random forest classifiers had similar performance (AUC values .746, .745 and .747, respectively) for predicting revision ESS. The best performance was yielded by using logistic regression and long predictor data retrieval time (AUC .809, precision 36%, sensitivity 70%) as compared with data collection time from baseline visit until 0, 3 and 6 months after the baseline ESS (AUC values .668, .717 and .746, respectively). The number of visits, number of days from the baseline visit to the baseline ESS, age, CRS with nasal polyps (CRSwNP), asthma, NERD and immunodeficiency or its suspicion were associated with revision ESS. Age and the number of visits before baseline ESS had non-linear effects for the predictions. **Conclusions:** Intelligent data analysis found important predictors of revision ESS at the individual level, such as visit frequency, age, Type 2 high diseases and immunodeficiency or its suspicion.

Running title:

Machine learning for prediction of revision paranasal sinus surgery

Mikko Nuutinen¹, DTech. Jari Haukka², PhD, Paula Virkkula³, MD PhD, Paulus Torkki², PhD, Sanna Toppila-Salmi^{1,4}

¹Haartman Institute, University of Helsinki, Helsinki, Finland

²Department of Public Health, University of Helsinki, Finland

³Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

⁴Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Corresponding author:

Sanna Toppila-Salmi, MD PhD, Skin and Allergy Hospital, Helsinki University Hospital, P.O. Box 160, 00029 HUS, Finland

Phone number: +358-9-4711

Telefax number: +358-9-19125155

E-mail address: sanna.salmi@helsinki.fi

Sources of funding:

This work was supported in part by research grants from Paulo Foundation, State funding for university-level health research (TYH2019322), The Finnish Anti-Tuberculosis Association Foundation, The Tampere Tuberculosis Foundation, and The Vainö and Laina Kivi Foundation. All in Finland.

Declaration of Interests:

STS reports a grant of GSK and consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma and Roche. All these are outside the submitted work. All other authors declare no conflicts of interest.

Word count of the text : 3455/3500.

Word count of the abstract : 249/250.

No. of tables/figures: 3 tables and 3 figures.

Supporting information : Text, 8 figures, 3 tables

Abstract

Background: Uncontrolled chronic rhinosinusitis (CRS) needing consideration of surgery is a growing health problem yet its risk factors at individual level are not known. Our aim was to examine risk factors of revision endoscopic sinus surgery (ESS) at the individual level by using artificial intelligence.

Methods: Demographic and visit variables were collected from electronic health records (EHR) of 790 operated CRS patients. The effect of variables on the prediction accuracy of revision ESS was examined at the individual level via machine learning models.

Results: Revision ESS was performed to 114 (14.7%) CRS patients. The logistic regression, gradient boosting and random forest classifiers had similar performance (AUC values .746, .745 and .747, respectively) for predicting revision ESS. The best performance was yielded by using logistic regression and long predictor data retrieval time (AUC .809, precision 36%, sensitivity 70%) as compared with data collection time from baseline visit until 0, 3 and 6 months after the baseline ESS (AUC values .668, .717 and .746, respectively). The number of visits, number of days from the baseline visit to the baseline ESS, age, CRS with nasal polyps (CRSwNP), asthma, NERD and immunodeficiency or its suspicion were associated with revision ESS. Age and the number of visits before baseline ESS had non-linear effects for the predictions.

Conclusions: Intelligent data analysis found important predictors of revision ESS at the individual level, such as visit frequency, age, Type 2 high diseases and immunodeficiency or its suspicion.

Keywords: chronic rhinosinusitis, endoscopic sinus surgery, machine learning, personalized prediction, revision surgery

Abbreviations used

AUC	Area Under Curve
CRS	Chronic rhinosinusitis
CRSwNP	Chronic rhinosinusitis with nasal polyps
ERH	Electronic health records
ESS	Endoscopic sinus surgery
PDP	Partially dependence plots
ROC	Receiver operator characteristic
SFS	Sequential forward selection
SHAP	Shapley values

Introduction

Chronic rhinosinusitis (CRS) is a symptomatic inflammatory disease of the nasal and paranasal mucosal lasting more than 12 weeks¹. It has a prevalence of about 11% and a remarkable impact on health and costs¹. The main phenotypes are CRS with nasal polyps (CRSwNP) and without (CRSSNP)¹⁻³. The majority of western CRS cases are characterized by type 2 -high inflammation with elevated levels of eosinophils, interleukin-4 (IL-4), IL-5 and IL-13¹. Endoscopic sinus surgery (ESS) has shown to be cost-effective treatment⁴, if conservative therapy (such as intranasal corticosteroids and nasal saline irrigation) is insufficient¹. About a sixth of patients respond unsatisfactory to initial ESS and require revision ESS¹.

Early identification of the risk of CRS recurrence after ESS is cost-effective^{5,6}. It helps target treatment correctly³⁹ and prevent permanent tissue changes¹. A substantial number of studies have identified risk factors of revision ESS⁷⁻¹⁵. The studies vary according to sample sizes (n=66¹⁵ or n=61000⁹), variable collection (large retrospective data base⁹ or prospective questionnaires⁸) or geographic locations (such as US⁹, Australia¹⁶ or Finland⁷). The commonly recognized risk factors include nasal polyps, asthma, allergy, non-steroidal anti-inflammatory drug (NSAID), exacerbated respiratory disease (NERD) and previous ESS. In a meta-analysis¹³, the strongest predictors of revision ESS were allergic fungal rhinosinusitis, NERD, asthma, prior polypectomy. However, no prior research has analysed the prediction accuracy of revision ESS at the individual level or for variables having a non-linear association.

The aim of this study was to examine accuracy of personalized prediction of revision ESS, and to identify most important predictor variables via modern machine learning algorithms.

Methods

Patients

This study was carried out of the rhinitis or rhinosinusitis patients visiting Departments of Otorhinolaryngology at the Hospital District of Helsinki and Uusimaa (HUS), Finland. The study (nro 31/13/03/00/2015) was approved by the ethical committee of the Hospital District. Ethics committee provided an approval that there was no need for written informed consent for this retrospective follow-up study.

The inclusion criterion of the initial patient population (n = 5080) was the ICD-10 diagnosis of J30., J31., J32., J33. or J01 registered in outpatient visits for the years 2005, 2007, 2009, 2011 or 2013. Longitudinal data of random patient samples were collected from electronic health records (EHR), so that the sample size was the same for each sampling year and each month of the sampling year. The last data collection day of the follow-up data was 31.9.2019. CRS was defined as having the diagnosis codes of J33. and/or J32. ESS was defined by the operation codes (Table S2). The baseline visit was defined as the first visit, and baseline ESS was the first ESS, found in the EHR at the given sampling time. Revision ESS was defined as ESS that was performed after the baseline ESS during the follow-up.

A total of 114/790 (14.7%) CRS patients underwent revision ESS in (mean±stdev) 30.3±31.0 months after the baseline ESS (Figure S3A, Table S4). Of the revised patients 91 had one revision ESS and 23 patients had two or more revisions (Figure S3B).

Variables

The patient variables (Table 1) were processed both from the structured and coded EHR data (visits, procedure codes and diagnoses of the patients) and free clinical texts (diagnoses and comorbidities, Figure S2, Table S1). Comorbidity-related variables were obtained from ICD-10 codes (Table S3) and by using validated keyword-based information extraction from free clinical texts (Please see further methods in this article's supporting information). For asthma we used ICD-10 codes J45., which is doctor-diagnosed lung-function test -confirmed asthma. NERD diagnosis was obtained from EHR text and was based on typical history of airway symptoms after ingestion of NSAID ± challenge test confirmation of NERD.

Machine learning algorithms

Univariate logistic regression models were used to study the prediction accuracy of individual variables. Predictive performance was compared between three classifiers: random forest, logistic regression and extreme gradient boosting. The effect of variable collection time on predictive performance was studied by using logistic regression classifier. Shapley values (SHAP)¹⁷ were used to rank the important variables for the trained classifier. Partially dependence plots (PDP)¹⁸ were used to explore how the predictions of the trained classifier partially depend on the values of variables (Please see further methods in this article’s supporting information).

Results

The CRS patient population who underwent baseline ESS (n=790) consisted of 460 (58%) females, and the age ranged from 6 to 90 years. The following comorbidities were significantly associated with the group who underwent revision ESS in the follow-up: doctor-diagnosed lung-function test -confirmed asthma, CRSwNP, allergy, chronic respiratory disease, and EHR text -based NERD and immunodeficiency or its suspicion (Table 1). The following continuous variables were significantly associated with revision ESS: higher age, shorter time from the baseline visit to the baseline ESS, higher visit frequency between the baseline visit to the baseline ESS and higher number of visits from the baseline ESS to 3 months postoperatively, 6 months postoperatively and 12 months postoperatively (Table 1).

Univariate analyses

The variables were entered in univariate logistic regression classifier to predict revision ESS after baseline ESS. Of the continuous variables, the highest AUC values were for the number of visits 12, 6, and 3 months after the baseline visit (AUC = .76, .69, .65, respectively, Table 2). The next highest AUC values were for the time between baseline visit and baseline ESS (AUC = .59) and, visit frequency from baseline visit to baseline ESS (AUC = .59). Of the categorical variables, the highest AUC values were for CRSwNP (AUC = .65), asthma (AUC = .65), immunodeficiency or its suspicion (AUC = .61), allergy (AUC = .61) and NERD (AUC = .60). The coefficients of the continuous variables were positive with one exception, which indicated that a higher visit number/frequency and, a shorter time between baseline visit and baseline ESS, increased revision ESS probability (Table 2)

Machine learning classifier comparison

We next applied sequential forward selection (SFS) method to select variables collected from the baseline visit until 6 months after the baseline ESS for the three classifiers: random forest, logistic regression and gradient boosting. The AUC values and F1-score values of the trained classifiers were averages from 10 reformations of training and test folds (Figure S1A). Performance values first increased fast and then reached the plateau as a function of the number of variables (Figure 1, Tables S5, S6). For the logistic regression classifier the highest average AUC (.746) and the highest F1-score (.404) were achieved with six and eleven variables, respectively. For the gradient boosting classifier the highest AUC (.745) was with twelve variables and F1-score (.407) was with three variables. For the random forest classifier the highest AUC (.747) was with fifteen and F1-score (.409) was with twelve variables.

The best variable selected by SFS (e.g. with highest AUC) of each run was given 15 points, the next best variable 14 points, and so on. A rank score (varying between 0-150 points) was formed from the sum of the points for each variable (see Eq. S1, in this article’s supporting information) after 10 reformations of training and test folds. When using any of the three classifiers, the following variables had the highest rank scores and were thus the most important predictors: the number of visits 6 months after the baseline ESS, CRSwNP, NERD and asthma (Table 3). When using the logistic regression classifier, the visit frequency from baseline visit to baseline ESS and, the time between baseline visit and baseline ESS were also important (Table 3).

Effect of the data collection time

We examined the effect of the length of data collection time on the model’s ability to predict revision ESS risk by using only Logistic Regression model (Figure 2), because the three classifiers performed with a similar pattern and with a fair discrimination ability (the highest AUC values between 0.7-0.8, see Figure 1). We

found that the highest AUC value was obtained when the variable data were collected from the baseline visit until 12 months after the baseline ESS (.81, Figure 2, Table S7), as compared with data collection time from baseline visit until 0, 3 and 6 months after the baseline ESS.

Interpretability analysis

Logistic regression classifier is linear and thus not able to model possible non-monotonic relations between predictors and outcome. Random forest and gradient boosting classifiers are able model complex, non-monotonous relations, but they are so called black box models which means non-interpretable classifiers. Relations between inputs and output are difficult to understand directly from the parameters or structure of trained model. Hence, SHAP values and PDP plots were used to conduct post-hoc interpretability analysis for the random forest classifier. SHAP values enable to calculate exactly for the tree classifiers (such as random forest) by using the mature treeSHAP method¹⁷.

We performed data flow (Figure S1B) to train the random forest classifier and calculated SHAP values of the variables collected from the baseline visit until 6 months after the baseline ESS. Figure 3 shows variables sorted by the highest sum of absolute SHAP values over all patients. The distributions of the data points on the plots show the impacts of each variable for the classifier output. We detected that high number of visits after baseline ESS and short time between baseline visit and baseline ESS both increased the revision ESS risk. In addition, CRSwNP, asthma and NERD increased revision ESS risk. SHAP values show that the age of patients and the visit frequency from baseline visit to baseline ESS affected revision ESS risk in a non-monotonic way. That is, the red values (the higher than the average values) of these variables are dispersed on both sides of the scale (Figure 3).

We formed PDP plots of the ten variables with the highest SHAP values. The plots of the following variables showed a large risk score scale for a revision ESS: the number of visits 6 (or 3) months after the baseline ESS, the time between baseline visit and baseline ESS, age, the number of visits between baseline visit and baseline ESS, CRSwNP and asthma. The average predicted risk score varied more than .02 units between the low and high value of these predictors, whereas for the other predictors the PDP risk score varied less than .02 units (Figure S4). The PDP plot of the number of visits 6 months after the baseline ESS, showed a large scale of the risk score ranging from value of .1 for patients with less than two visits after baseline ESS, up to a value of about .35 for patients with more than seven visits (Figure S4A). Similarly, if patient had two or more postoperative visits within the 3 months, the risk score for revision ESS increased (Figure S4D). The plot of the time between baseline visit and baseline ESS showed a sharp drop of the risk score after about 100 days (Figure S4F). When the time between baseline visit and ESS was less than 100 days, the risk score was about .15. When the time increases to > 500 days, the risk score decreases to < .13. The PDP curve for age was non-monotonic and the risk scores varied from .1 for patients with age from 10-30 years, to about .17 for patients with age from 60-70 years (Figure S4E). The risk scores were .13- .15 for patients with age from 30-60 or over 70 years. The number of visits between baseline visit and baseline ESS was non-monotonic. The patients with 10-20 visits between the baseline visit and baseline ESS had smaller risk for revision ESS than the patients with less than 10 or more than 20 visits (Figure S4I).

Discussion

This study was carried out to evaluate the personalized risk factors of revision ESS for CRS patients. By using machine learning algorithms we discovered novel, previously unpublished, important variables predicting revision ESS, such as high number of visits before and after the baseline ESS and, short time between the baseline visit and baseline ESS. Our data also demonstrated that demographic variables of age, Type 2 high diseases (CRSwNP, asthma, NERD) and immunodeficiency or its suspicion, were important predictors of revision ESS at the individual level, which is in line to previous observations at the population level¹⁹.

None of the previous studies have presented models designed to predict revision ESS at the individual level and for non-linear predictors. Success rate for initial ESS range from 76% to 98%^{20,21}. Revision ESS risk has previously been studied at the population level by using such as Cox's proportional hazard^{7,9,10} or logistic regression^{8,9,12,14} models, which usually assume that associations are linear and that an alpha error < 5%

indicates importance of a predictor.

Increased number of visits, increased visit frequency, and short time between the baseline visit and the baseline ESS, were associated with revision ESS. Our findings suggest that increased visits before ESS might signal to a more severe disease that seems not only to affect to the physician's and patient's decision of ESS at baseline but also that of revision ESS in the follow-up. The results reflect that patients who achieved disease control after the baseline ESS did not need any more follow-up visits at Tertiary care and were unsubscribed from the hospital, whereas those with continuous problems visit more frequently and have higher probability to end up with revision ESS. There is little literature evidence of the predictive potential of visit variables at the individual level. A retrospective cohort study from US ($n = 6985$) showed that the number of post-operative outpatient visits was associated with revision surgery of anterior cruciate ligament reconstructions²². The findings are thus similar findings to ours, in other surgery and in population level. Our findings that patients who have a high visit frequency at baseline are in a higher risk to be only partially controlled by surgery, might be helpful in patient counseling.

The current study showed that CRSwNP, asthma, and NERD are important predictors of revision ESS also at the individual level. In accordance to this, previous studies have demonstrated on hospital population level that several factors are associated with the CRS recurrence and/or revision ESS, such as CRSwNP, asthma, AR, NERD, eosinophilia and smoking^{1,7,23,24}. CRSwNP patients with co-morbid asthma and/or NERD have an increased risk for recurrence and revision ESS, although these patients seem benefit from initial ESS^{13,19,25–27}. This may reflect a more severe disease, with usually co-morbid NERD, anosmia, Type 2 high eosinophilic inflammation, and a greater tendency of polyp re-growth^{23,28–37}. When performing SFS, Immunodeficiency or its suspicion showed also to one of the top ten predictors by all three classifiers. This is in line to previous study that has shown on hospital population level that immunodeficiency and granulomatosis with polyangiitis increase the revision ESS risk³⁸.

We showed that the length of EHR data collection time increased the predictive accuracy of the models. Data collection time from the baseline visit until 12 months after the baseline ESS had the highest predictive accuracy in our models. Time span of data collection for the model is an optimization task between required time slot after baseline ESS and model accuracy.

We validated the predictive accuracy by using three classifiers. We chose in this study to use logistic regression, gradient boosting and random forest -classifiers as they have different properties as and have been generally used in prediction of such as surgery outcomes^{39, 40} or persistent asthma⁴¹. Logistic regression classifier is linear and thus not able to model possible nonmonotonic and non-linear relations between predictors and outcome⁴². Random forest and gradient boosting classifiers can model complex relations, but they are so called black box models which means non-interpretable classifiers, which means relations between their inputs and output are difficult to understand directly from the parameters or structure of trained model⁴². As the predictive accuracy of the variables was similar by the three classifiers in our study, logistic regression was mainly used in validation of variable collection time. Altogether, our findings point out the importance of validating outcome prediction by using different classifiers and evaluating the effect of data collection time, as has also been suggested in previous literature^{43,44}.

The study groups of ours and others have previously demonstrated that younger age is associated with revision ESS on hospital populations of CRSwNP³² or CRS⁷ patients. In the present study we found that age actually affects revision ESS risk in a non-monotonic way. Hence, logistic regression models seems not solely ideal to study the effect of the individual patient's age on revision ESS risk. By performing partial dependency plots analysis we showed that the revision ESS risk was the highest for patients with age from 60-70 years, and medium high from 30-60 years or over 70 years, whereas the risk was the lowest from 10-30 years of age. Younger patients have less CRSwNP, or their CRSwNP often comprises antrochoanal polyps, which have shown to bear a smaller revision surgery risk¹. An increased risk of revision ESS between 60-70 years may be related to worsening of CRS and/or comorbidities, such as asthma. Studies have shown that CRS is more frequent in severe asthma phenotype in the oldest subjects⁴⁵. In addition, the number of visits before baseline ESS had non-linear effects for the predictions in our study. Patients with 10-20 visits between

the baseline visit and baseline ESS had smaller risk for revision ESS than the patients with less than 10 or more than 20 visits. Those patients visiting 10-20 times before baseline ESS, would possibly have CRSsNP with acute recurrent exacerbations, yet this subgroup warrants confirmation in further studies as the number of subjects in this study was small. Previous studies have shown that CRSsNP patients with recurrent acute rhinosinusitis episodes, benefits from initial ESS¹. Previous studies exist of other conditions and of other predictors showing U-shaped association between predictor variable and outcome, such as intraoperative net fluid balance and early atrial tachyarrhythmia recurrence⁴⁶, and body mass index and asthma in Japanese children⁴⁷. These findings point out the importance of evaluating the linearity of the association to improve personalized prediction.

There is a high need to detect risk factors of severity and to organize personalized patient care. Artificial intelligence has shown to be effective in EHR-based research of allergy, asthma, and immunology research⁴⁸, such as to predict eosinophilic esophagitis⁴⁹, and early childhood asthma persistence⁴¹. As far as we know, machine learning models have been used only in few previous CRS studies, to classify osteomeatal complex inflammation on computed tomography⁵⁰ and olfactory recovery after ESS⁵¹. In surgery research, machine learning models have been used to predict surgical site infections⁵², postoperative outcome of degenerative cervical myelopathy³⁹, revision surgery after knee replacement⁵³, prolonged opioid prescription after surgery for lumbar disc herniation⁵⁴, and blood transfusion after adult spinal deformity surgery⁵⁵.

The strengths of this study include random sample of hospital patients, long follow-up time and discovery of non-linear associations between certain variables and outcome. In addition, a novelty is that the models were validated by several classifiers and were tested at the individual level.

Limitations include the small number of patients, yet this was compensated by the cross-validation methods. In addition, patients from only one unit, i.e., generalization of results, should be ensured in a further study with an expanded data set. We acknowledge that we lacked the data of some important factors such as validated symptoms, endoscopic nasal polyp score, medication, Lund Mackay score of sinus computed tomography scans, eosinophils, and extent of baseline ESS. The inclusion of these variables would most probably have improved the estimates. Our analysis of revision surgery may have been influenced by several factors unrelated to recurrence of CRS, including wait-times, operative technique, and surgeons/patients' personal preferences. Public medical care covers over 90% of our operations⁵⁶ thus minimizing possibility of bias due to loss of follow up, yet we acknowledge that some individual patients with recurrence may have sought treatment elsewhere. Despite these limitations, we found that intelligent data analysis is feasible to obtain individual probability of revision ESS, and thus could help in informing discussions and decision making of advanced therapy, such as biologicals⁵⁷.

Conclusions

Our results suggest that Type 2-high conditions (CRSwNP, asthma, NERD), high visit frequency, short time between baseline visit and ESS, and immunodeficiency or its suspicion increase likelihood of revision ESS at individual level. Moreover, age and the number of preoperative visits predict non-linearly the revision ESS risk. These data could be usable in clinical decision making and patient counseling.

References

- [1] Fokkens W, Lund V, Hopkins C, Hellings P, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, et al. 2020 European position paper on rhinosinusitis and nasal polyps 2020. *Rhinology journal* 58, 1–464. (doi:10.4193/Rhin20.600).
- [2] Liao B, Liu JX, Li ZY, Zhen Z, Cao PP, Yao Y, Long XB, Wang H, Wang Y, Schleimer R, et al. 2018 Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. *Allergy* 73, 7, 1459–1469. (doi:https://doi.org/10.1111/all.13411).
- [3] Wei B, Liu F, Zhang J, Liu Y, Du J, Liu S, Zhang N, Bachert C, Meng J. 2018 Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a chinese population. *Rhinology* 56, 3, 216–226. (doi:10.4193/rhin17.240).

- [4] Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith TL. 2015 Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. *The Laryngoscope* 125, 1, 25–32. (doi:<https://doi.org/10.1002/lary.24916>).
- [5] Anderson WC, Szeffler SJ. 2019 Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic. *Annals of allergy, asthma and immunology* 122, 4, 367–372. (doi:[10.1016/j.anai.2019.01.018](https://doi.org/10.1016/j.anai.2019.01.018)).
- [6] Guo C, Liao B, Liu J, Pan L, Z L. 2021 Predicting difficult-to-treat chronic rhinosinusitis by noninvasive biological markers. *Rhinology* 59, 1, 81–90. (doi:[10.4193/Rhin20.103](https://doi.org/10.4193/Rhin20.103)).
- [7] Koskinen A, Salo R, Huhtala H, Myller J, Rautiainen M, Kääriäinen J, Penttilä M, Renkonen R, Raitiola H, Mäkelä M, et al. 2016 Factors affecting revision rate of chronic rhinosinusitis. *Laryngoscope Investigative Otolaryngology* 1, 4, 96–105. (doi:[10.1002/lio2.27](https://doi.org/10.1002/lio2.27)).
- [8] Rudmik L, Soler ZM, Hopkins C. 2016 Using postoperative snot-22 to help predict the probability of revision sinus surgery. *Rhinology* 54, 2, 111–116. (doi:[10.4193/rhin15.284](https://doi.org/10.4193/rhin15.284)).
- [9] Stein NR, Jafari A, DeConde AS. 2018 Revision rates and time to revision following endoscopic sinus surgery: A large database analysis. *The Laryngoscope* 128, 1, 31–36. (doi:[10.1002/lary.26741](https://doi.org/10.1002/lary.26741)).
- [10] Smith KA, Orlandi RR, Oakley G, Meeks H, Curtin K, Alt JA. 2019 Long-term revision rates for endoscopic sinus surgery. *International Forum of Allergy & Rhinology* 9, 4, 402–408. (doi:[10.1002/alr.22264](https://doi.org/10.1002/alr.22264)).
- [11] Younis RT, Ahmed J. 2017 Predicting revision sinus surgery in allergic fungal and eosinophilic mucin chronic rhinosinusitis. *The Laryngoscope* 127, 1, 59–63. (doi:[10.1002/lary.26248](https://doi.org/10.1002/lary.26248)).
- [12] Loftus CA, Soler ZM, Desiato VM, Koochakzadeh S, Yoo F, Storck KA, Schlosser RJ. 2020 Factors impacting revision surgery in patients with chronic rhinosinusitis with nasal polyposis. *International Forum of Allergy & Rhinology* 10, 3, 289–302. (doi:[10.1002/alr.22505](https://doi.org/10.1002/alr.22505)).
- [13] Loftus CA, Soler ZM, Koochakzadeh S, Desiato VM, Yoo F, Nguyen SA, Schlosser RJ. 2020 Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. *International Forum of Allergy & Rhinology* 10, 2, 199–207. (doi:[10.1002/alr.22487](https://doi.org/10.1002/alr.22487)).
- [14] Veloso-Teles R, Cerejeira R. 2017 Endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: Clinical outcome and predictive factors of recurrence. *American Journal of Rhinology & Allergy* 31, 1, 56–62. (doi:[10.2500/ajra.2017.31.4402](https://doi.org/10.2500/ajra.2017.31.4402)).
- [15] Mueller S, Wendler O, Nocera A, Grundtner P, Schlegel P, Agaimy A, Iro H, Bleier B. 2019 Escalation in mucus cystatin 2, pappalysin-a, and periostin levels over time predict need for recurrent surgery in chronic rhinosinusitis with nasal polyps. *International Forum of Allergy & Rhinology* 9, 1212 – 1219.
- [16] Morrissey DK, Bassiouni A, Psaltis AJ, Naidoo Y, Wormald PJ. 2016 Outcomes of modified endoscopic-pneumolysis in aspirin-exacerbated respiratory disease with nasal polyposis. *International Forum of Allergy & Rhinology* 6, 8, 820–825. (doi:[10.1002/alr.21739](https://doi.org/10.1002/alr.21739)).
- [17] Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Himmelfarb J, Bansal N, Lee SI. 2020 From local explanations to global understanding with explainable ai for trees. *Nature Machine Intelligence* 2, 1, 2522–5839.
- [18] Friedman JH. 2001 Greedy function approximation: A gradient boosting machine. *The Annals of Statistics* 29, 5, 1189–232.
- [19] Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW. 2011 Revision rates after endoscopic sinus surgery: A recurrence analysis. *Annals of Otolaryngology, Rhinology & Laryngology* 120, 3, 162–166. (doi:[10.1177/000348941112000304](https://doi.org/10.1177/000348941112000304)). PMID: 21510141.

- [20] Chang CC, Tai CJ, Ng TY, Tsou YA, Tsai MH. 2014 Can fess combined with submucosal resection (smr)/septoplasty reduce revision rate? *Otolaryngology–Head and Neck Surgery* 151, 4, 700–705. (doi: 10.1177/0194599814543778). PMID: 25146305.
- [21] Hopkins C, Browne J, Slack R, Lund V, Topham J, Reeves B, Copley L, Brown P, Van Der Meulen J. 2006 The national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. *Clinical Otolaryngology* 31, 5, 390–398. (doi:<https://doi.org/10.1111/j.1749-4486.2006.01275.x>).
- [22] Inacio MC, Cafri G, Funahashi TT, Maletis GB, Paxton EW. 2016 Type and frequency of healthcare encounters can predict poor surgical outcomes in anterior cruciate ligament reconstruction patients. *International Journal of Medical Informatics* 90, 32–39. (doi: <https://doi.org/10.1016/j.ijmedinf.2016.03.005>).
- [23] Lilja MJ, Koskinen A, Virkkula P, Vento SI, Myller J, Hammaren-Malmi S, Laulajainen-Hongisto A, Hytonen M, Makitie A, Numminen J, et al. 2021 Factors affecting the control of chronic rhinosinusitis with nasal polyps: A comparison in patients with or without nerd. *Allergy & Rhinology* 12, 21526567211003844. (doi:10.1177/21526567211003844).
- [24] Virkkula P, Penttila E, Vento S, Myller J, Koskinen A, Hammaren-Malmi S, Laulajainen-Hongisto A, Hytonen M, Lilja M, Numminen J, et al. 2020 Assessing cut-off points of eosinophils, nasal polyp, and lund-mackay scores to predict surgery in nasal polyposis: A real-world study. *Allergy and Rhinology* 11.
- [25] Zhang L, Zhang Y, Gao Y, Wang K, Lou H, Meng Y, C CW. 2020 Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma. *Rhinology* 58, 2. (doi:10.4193/Rhin19.184).
- [26] van der Veen J, Seys SF, Timmermans M, Levie P, Jorissen M, Fokkens WJ, Hellings PW. 2017 Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. *Allergy* 72, 2, 282–290. (doi:<https://doi.org/10.1111/all.12983>).
- [27] Laulajainen-Hongisto A, Turpeinen H, Vento SI, Numminen J, Sahlman J, Kauppi P, Virkkula P, Hytönen M, Toppila-Salmi S. 2020 High discontinuation rates of peroral asa treatment for crswnp: A real-world multicenter study of 171 n-erd patients. *The Journal of Allergy and Clinical Immunology: In Practice* 8, 10, 3565–3574. (doi:<https://doi.org/10.1016/j.jaip.2020.06.063>).
- [28] Steinke JW, Payne SC, Borish L. 2016 Eosinophils and mast cells in aspirin-exacerbated respiratory disease. *Immunology and Allergy Clinics of North America* 36, 4, 719–734. (doi: <https://doi.org/10.1016/j.jiac.2016.06.008>). Aspirin-Exacerbated Respiratory Disease.
- [29] Brescia G, Barion U, Zanotti C, Giacomelli L, Martini A, Marioni G. 2017 The prognostic role of serum eosinophil and basophil levels in sinonasal polyposis. *International Forum of Allergy & Rhinology* 7, 3, 261–267. (doi:<https://doi.org/10.1002/alr.21885>).
- [30] Lou H, Meng Y, Piao Y, Wang C, Zhang L, Bachert C. 2015 Predictive significance of tissue eosinophilia for nasal polyp recurrence in the chinese population. *American Journal of Rhinology & Allergy* 29, 5, 350–356. (doi:10.2500/ajra.2015.29.4231).
- [31] Brescia G, Pedruzzi B, Barion U, Cinetto F, Giacomelli L, Martini A, Marioni G. 2016 Are neutrophil-, eosinophil-, and basophil-to-lymphocyte ratios useful markers for pinpointing patients at higher risk of recurrent sinonasal polyps? *American Journal of Otolaryngology* 37, 4, 339–345. (doi: <https://doi.org/10.1016/j.amjoto.2016.02.002>).
- [32] Brescia G, Marioni G, Franchella S, Ramacciotti G, Giacomelli L, Marino F, Martini A. 2016 A prospective investigation of predictive parameters for post-surgical recurrences in sinonasal polyposis. *Archiv für Klinische und Experimentelle Ohren- Nasen- und Kehlkopfheilkunde* 273, 655–660. (doi:10.1007/s00405-015-3598-5).
- [33] Tao X, Chen F, Sun Y, Wu S, Hong H, Shi J, Xu R. 2018 Prediction models for postoperative uncontrolled chronic rhinosinusitis in daily practice. *The Laryngoscope* 128, 12, 2673–2680. (doi: <https://doi.org/10.1002/lary.2673>).

[ps://doi.org/10.1002/lary.27267](https://doi.org/10.1002/lary.27267)).

- [34] Vlaminc S, Vauterin T, Hellings PW, Jorissen M, Acke F, Cauwenberge PV, Bachert C, Gevaert P. 2014 The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: A 3-year prospective observational study. *American Journal of Rhinology & Allergy* 28, 3, 260–264. (doi: 10.2500/ajra.2014.28.4024).
- [35] Nakayama T, Yoshikawa M, Asaka D, Okushi T, Matsuwaki Y, Otori N, Hama T, Moriyama H. 2011 Mucosal eosinophilia and recurrence of nasal polyps - new classification of chronic rhinosinusitis. *Rhinology* 49, 4, 392–396. (doi:10.4193/rhino10.261).
- [36] Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, Saitoh T, Murata J. 2013 Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil. *The Laryngoscope* 123, 11, E1–E9. (doi:<https://doi.org/10.1002/lary.24154>).
- [37] Lyly A, Laulajainen-Hongisto A, Turpeinen H, Vento SI, Myller J, Numminen J, Sillanpää S, Sahlman J, Kauppi P, Toppila-Salmi S. 2021 Factors affecting upper airway control of nsaid-exacerbated respiratory disease: A real-world study of 167 patients. *Immunity, Inflammation and Disease* 9, 1, 80–89. (doi: <https://doi.org/10.1002/iid3.347>).
- [38] Miglani A, Divekar RD, Azar A, Rank MA, Lal D. 2018 Revision endoscopic sinus surgery rates by chronic rhinosinusitis subtype. *International Forum of Allergy & Rhinology* 8, 9, 1047–1051. (doi: <https://doi.org/10.1002/alr.22146>).
- [39] Merali ZG, Witiw CD, Badhiwala JH, Wilson JR, Fehlings MG. 2019 Using a machine learning approach to predict outcome after surgery for degenerative cervical myelopathy. *PLOS ONE* 14, 4, 1–12. (doi: 10.1371/journal.pone.0215133).
- [40] Jalali A, Lonsdale H, DNPJGMKSGSJRMAL. 2020 Deep learning for improved risk prediction in surgical outcomes. *Sci Rep.* 10, 9289. (doi:10.1038/s41598-020-62971-3).
- [41] Bose S, Kenyon CC, Masino AJ. 2021 Personalized prediction of early childhood asthma persistence: A machine learning approach. *PLOS ONE* 16, 3, 1–17. (doi:10.1371/journal.pone.0247784).
- [42] Hastie T, Tibshirani R, Friedman J. 2008 *The Elements of Statistical Learning*. Springer Series in Statistics. New York, NY, USA: Springer New York Inc.
- [43] Nuutinen M, Leskelä RL, Suojalehto E, Tirronen A, Komssi V. 2017 *Bmc med inform decis mak*. Development and validation of classifiers and variable subsets for predicting nursing home admission 39. (doi:10.1186/s12911-017-0442-4).
- [44] Hamerla G, Meyer HJ, Schob S, Ginat DT, Altman A, Lim T, Gihl GA, Horvath-Rizea D, Hoffmann KT, Surov A. 2019 Comparison of machine learning classifiers for differentiation of grade 1 from higher gradings in meningioma: A multicenter radiomics study. *Magnetic Resonance Imaging* 63, 244–249. (doi: <https://doi.org/10.1016/j.mri.2019.08.011>).
- [45] Moore W, Meyers D, Wenzel S. 2010 Identification of asthma phenotypes using cluster analysis in the severe asthma research program. *Am J Respir Crit Care Med* 133, 1557–1563.
- [46] Minami K, Kabata D, Kakuta T, Fukushima S, Fujita T, Shintani A, Yoshitani K, Ohnishi Y. 2020 U-shaped association between intraoperative net fluid balance and risk of postoperative recurrent atrial tachyarrhythmia among patients undergoing the cryo-maze procedure: An observational study. *Journal of Cardiothoracic and Vascular Anesthesia* (doi:10.1053/j.jvca.2020.10.023).
- [47] Tanaka K, Miyake Y, Arakawa M, Sasaki S, Ohya Y. 2011 U-shaped association between body mass index and the prevalence of wheeze and asthma, but not eczema or rhinoconjunctivitis: The Ryukyus child health study. *The Journal of asthma : official journal of the Association for the Care of Asthma* 48, 804–10. (doi:10.3109/02770903.2011.611956).

- [48] Juhn Y, Liu H. 2019 Natural language processing to advance ehr-based clinical research in allergy, asthma, and immunology. *Journal of Allergy and Clinical Immunology* 145. (doi: 10.1016/j.jaci.2019.12.897).
- [49] Sallis BF, Erkert L, Moñino-Romero S, Acar U, Wu R, Konnikova L, Lexmond WS, Hamilton MJ, Dunn WA, Szepfalusi Z, et al. 2018 An algorithm for the classification of mrna patterns in eosinophilic esophagitis: Integration of machine learning. *Journal of Allergy and Clinical Immunology* 141, 4, 1354–1364.e9. (doi:<https://doi.org/10.1016/j.jaci.2017.11.027>).
- [50] Chowdhury NI, Smith TL, Chandra RK, Turner JH. 2019 Automated classification of osteomeatal complex inflammation on computed tomography using convolutional neural networks. *International Forum of Allergy & Rhinology* 9, 1, 46–52. (doi:<https://doi.org/10.1002/alar.22196>).
- [51] Katotomichelakis M, Gouveris H, Tripsianis G, Simopoulou M, Papathanassiou J, Danielides V. 2010 Biometric predictive models for the evaluation of olfactory recovery after endoscopic sinus surgery in patients with nasal polyposis. *American journal of rhinology and allergy* 24, 4, 276–280. (doi: 10.2500/ajra.2010.24.3476).
- [52] da Silva DA, ten Caten CS, dos Santos RP, Fogliatto FS, Hsuan J. 2019 Predicting the occurrence of surgical site infections using text mining and machine learning. *PLOS ONE* 14, 12, 1–17. (doi: 10.1371/journal.pone.0226272).
- [53] Aram P, Trela-Larsen L, Sayers A, Hills A, Blom A, McCloskey E, Kadirkamanathan V, Wilkinson J. 2018 Estimating an individual’s probability of revision surgery after knee replacement: A comparison of modeling approaches using a national data set. *American journal of epidemiology* 187. (doi:10.1093/aje/kwy121).
- [54] Karhade AV, Ogink PT, Thio QC, Cha TD, Gormley WB, Hershman SH, Smith TR, Mao J, Schoenfeld AJ, Bono CM, et al. 2019 Development of machine learning algorithms for prediction of prolonged opioid prescription after surgery for lumbar disc herniation. *The Spine Journal* 19, 11, 1764 – 1771. (doi: <https://doi.org/10.1016/j.spinee.2019.06.002>).
- [55] Durand WM, DePasse JM, Daniels AH. 2018 Predictive modeling for blood transfusion after adult spinal deformity surgery. *Spine* 43, 15, 1058 – 1066. (doi:10.1097/BRS.0000000000002515).
- [56] Toppila-Salmi S, Rihkanen H, Arffman M, Manderbacka K, Keskimäki I, Hytönen M. 2018 Regional differences in endoscopic sinus surgery in finland: A nationwide register-based study. *BMJ Open* 8, e022173. (doi:10.1136/bmjopen-2018-022173).
- [57] Lyly A, Laulajainen-Hongisto A, Gevaert P, Kauppi P, Toppila-Salmi S. 2020 Monoclonal antibodies and airway diseases. *International Journal of Molecular Sciences* 21, 24. (doi:10.3390/ijms21249477).

Table 1. Characteristics of patients without/with status of revision ESS. P values by Fisher’s exact test.

	No revision ESS	Revision ESS	P value
Female sex, n (%)	394 (58.28%)	66 (57.89%)	1
Asthma, n (%)	241 (35.65%)	68 (59.65%)	<0.001
Allergy, n (%)	238 (35.21%)	58 (50.88%)	0.001
Chronic respiratory diseases, n (%)	192 (28.4%)	43 (37.72%)	0.04
Mental disorders, n (%)	85 (12.57%)	17 (14.91%)	0.54
Memory disorders, n (%)	13 (1.92%)	3 (2.63%)	0.71
Cancer, n (%)	67 (9.91%)	17 (14.91%)	0.13
Cardiovascular disease, n (%)	221 (32.69%)	48 (42.11%)	0.05
Obesity, n (%)	61 (9.02%)	8 (7.02%)	0.59
Diabetes, n (%)	67 (9.91%)	14 (12.28%)	0.40
Musculoskeletal diseases, n (%)	258 (38.17%)	51 (44.74%)	0.21
NERD, n (%)	56 (8.28%)	22 (19.3%)	<0.001
Immunodeficiency, n (%)	3 (0.44%)	2 (1.75%)	0.15

	No revision ESS	Revision ESS	P value
Immunodeficiency or its suspicion, n (%)	18 (2.66%)	13 (11.4%)	<0.001
Obstructive sleep apnea, n (%)	56 (8.28%)	14 (12.28%)	0.21
Mouth breathing, n (%)	36 (5.33%)	11 (9.65%)	0.08
Gastroesophageal reflux, n (%)	43 (6.36%)	11 (9.65%)	0.22
CRSwNP, n (%)	206 (30.47%)	60 (52.63%)	<0.001
Age, baseline ESS, mean±SD	44.57 (16.71)	47.48 (15.12)	0.03
ASA value, mean±SD	1.68 ± 0.64	1.78 (0.65)	0.05
Time from the base line visit to the baseline ESS (days), mean±SD	567.51 ± 827.06	474.5 ± 758.66	<0.001
Number of visits from the baseline to the baseline ESS, mean±SD	4.27 ± 4.82	4.91 ± 7.61	0.25
Visit frequency between the baseline visit to the baseline ESS, mean±SD	8.7 ± 23.29	13.64 ± 38.14	<0.001
Number of visits before the baseline ESS (0-12months), mean±SD	2.82 ± 2.49	3.05 ± 3.28	0.41
Number of visits before the baseline ESS (0-6months), mean±SD	2.05 ± 1.95	2.43 ± 2.42	0.14
Number of visits from the baseline ESS to 3 months postoperatively, mean±SD	1.44 ± 1.24	2.31 ± 1.96	<0.001
Number of visits from the baseline ESS to 6 months postoperatively, mean±SD	1.88 ± 1.79	3.87 ± 3.65	<0.001
Number of visits from the baseline ESS to 12 months postoperatively, mean±SD	2.36 ± 2.52	6.18 ± 5.53	<0.001

ASA= physical status classification system, CRSwNP=chronic rhinosinusitis with nasal polyps, ESS=endoscopic sinus surgery, NERD=non-steroidal anti-inflammatory drug exacerbated respiratory disease, SD= standard deviation.

Table 2. Variable coefficients and performance values for univariate logistic regression models

Variable	Coef (95% CI)	AUC (95% CI)	Precision (Mean)
Number of visits from the baseline ESS to 12 months postop.	4.69 (4.63 - 4.75)	0.76 (0.75 - 0.77)	0.33
Number of visits from the baseline ESS to 6 months postop.	3.68 (3.61 - 3.75)	0.69 (0.68 - 0.7)	0.25
CRSwNP	0.92 (0.89 - 0.94)	0.65 (0.64 - 0.66)	0.22
Number of visits from the baseline ESS to 3 months postop.	2.37 (2.31 - 2.44)	0.65 (0.64 - 0.66)	0.21
Asthma	0.87 (0.83 - 0.9)	0.65 (0.64 - 0.66)	0.22
Immunodeficiency or its suspicion	1.22 (1.18 - 1.27)	0.61 (0.6 - 0.62)	0.19
Allergy	0.57 (0.55 - 0.6)	0.61 (0.6 - 0.62)	0.19
NERD	0.8 (0.77 - 0.84)	0.6 (0.6 - 0.61)	0.18
Mouth breathing	0.48 (0.43 - 0.53)	0.59 (0.58 - 0.6)	0.19
Chronic respiratory diseases	0.31 (0.28 - 0.33)	0.59 (0.58 - 0.6)	0.19
Visit frequency between the baseline visit to the baseline ESS	0.78 (0.69 - 0.87)	0.59 (0.58 - 0.6)	0.18
Obstructive sleep apnea	0.29 (0.25 - 0.33)	0.59 (0.58 - 0.59)	0.18
Time from the baseline visit to the baseline ESS (days)	-0.91 (-0.98 - -0.85)	0.59 (0.58 - 0.6)	0.19
Age	0.74 (0.68 - 0.8)	0.58 (0.58 - 0.59)	0.18
Number of visits before the baseline ESS (0-6 months)	0.55 (0.47 - 0.64)	0.58 (0.57 - 0.59)	0.18
Number of visits from the baseline to the baseline ESS	0.04 (-0.04 - 0.12)	0.58 (0.57 - 0.59)	0.18
Cancer	0.18 (0.14 - 0.21)	0.58 (0.57 - 0.59)	0.18
Cardiovascular disease	0.26 (0.23 - 0.29)	0.58 (0.57 - 0.59)	0.17
Gastroesophageal reflux	0.27 (0.23 - 0.32)	0.58 (0.57 - 0.59)	0.18
Immunodeficiency	0.42 (0.34 - 0.5)	0.58 (0.57 - 0.59)	0.18
Musculoskeletal diseases	0.13 (0.1 - 0.15)	0.58 (0.57 - 0.59)	0.17
Obesity	-0.39 (-0.44 - -0.34)	0.58 (0.58 - 0.59)	0.18
Memory disorders	0.11 (0.04 - 0.18)	0.58 (0.57 - 0.59)	0.18
Gender female	-0.06 (-0.09 - -0.03)	0.57 (0.56 - 0.58)	0.18
ASA value	0.38 (0.32 - 0.45)	0.57 (0.57 - 0.58)	0.18
Number of visits before the baseline ESS (0-12 months)	0.03 (-0.07 - 0.12)	0.57 (0.57 - 0.58)	0.18

Variable	Coef (95% CI)	AUC (95% CI)	Precision (Mean)
Diabetes	0.01 (-0.04 - 0.06)	0.57 (0.56 - 0.58)	0.18
Mental disorders	-0.05 (-0.09 - -0.01)	0.57 (0.56 - 0.58)	0.18

ASA= physical status classification system, CRSwNP=chronic rhinosinusitis with nasal polyps, ESS=endoscopic sinus surgery, NERD=non-steroidal anti-inflammatory drug exacerbated respiratory disease, postop.=postoperatively.

Table 3. Top-10 features selected for different classifiers by the SFS

Classifier	Variables	Score
Random forest	Number of visits from the baseline ESS to 6 months postoperatively	133
	Asthma	94
	CRSwNP	93
	NERD	85
	Immunodeficiency	84
	Age, baseline ESS	60
	Musculoskeletal diseases	56
	Immunodeficiency or its suspicion	54
	Obstr sleep apnea	52
	Cancer	51
Logistic regression	Number of visits from the baseline ESS to 6 months postoperatively	150
	CRSwNP	134
	Immunodeficiency or its suspicion	103
	NERD	90
	Time from the baseline visit to the baseline ESS (days)	76
	Asthma	74
	Visit frequency between the baseline visit to the baseline ESS	72
	Allergy	45
	ASA value	42
	Number of visits before the baseline ESS (0-12 months)	42
Gradient boosting	Number of visits from the baseline ESS to 6 months postoperatively	149
	CRSwNP	110
	Asthma	103
	Memory disorders	77
	Obesity	71
	Immunodeficiency	61
	NERD	57
	Immunodeficiency or its suspicion	54
	Cancer	51
	Mental disorders	48

ASA= physical status classification system, CRSwNP=chronic rhinosinusitis with nasal polyps, ESS=endoscopic sinus surgery, NERD=non-steroidal anti-inflammatory drug exacerbated respiratory disease.

Figure 1. AUC (a) and F1-score (b) as a number of variables for different classifiers. AUC = Area under the Receiver operating characteristic (ROC) -curve

Figure 2. ROC curves for logistic regression classifiers when data were collected from the baseline visit

until 0, 3, 6 and 12 months after the baseline ESS. AUC = Area under the Receiver operating characteristic (ROC) -curve

Figure 3. SHAP values for the ten most important (sum of the absolute SHAP values) variables for random forest classifier. The red points indicate higher and the blue points lower values than the average value of the variable. SHAP = Shapley value.



